VolitionRX Stock

VolitionRX EBIT

The EBIT of VolitionRX (VNRX) as of Aug 4, 2026 is -27.03 M USD. In the previous year, EBIT was -35.99 M USD — a change of -24.90% (higher).

EBIT

-27.03 MUSD

YoY

-24.90%

Last updated:

In 2026, VolitionRX's EBIT was -27.03 M USD, a -24.90% increase from the -35.99 M USD EBIT recorded in the previous year.

The VolitionRX EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2024
-27.03 base
Jan 1, 2025 (e)
-23.04 base
Jan 1, 2026 (e)
-14.01 base
Jan 1, 2027 (e)
26.94 base
Jan 1, 2028 (e)
91.38 base
Jan 1, 2029 (e)
153.45 base
Jan 1, 2030 (e)
218.32 base
Jan 1, 2031 (e)
0.00 base
YEAREBIT (M USD)
2031 est -
2030 est 218.32
2029 est 153.45
2028 est 91.38
2027 est 26.94
2026 est -14.01
2025 est -23.04
2024 -27.03
2023 -35.99
2022 -31.78
2021 -28.33
2020 -21.25
2019 -16.04
2018 -17.90
2017 -14.70
2016 -11.29
2015 -10.01
2014 -5.95
2013 -4.23
2012 -4.08
2011 -2.61
2010 -0.01
2009 -0.01
2008 -0.02
2007 -0.02
2006 -0.03
2005 -0.04
Access this data via the Eulerpool API

VolitionRX Revenue

VolitionRX Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
1.23 M USD
-27.03 M USD
-26.97 M USD
Jan 1, 2025 (e)
2.08 M USD
-23.04 M USD
-18.53 M USD
Jan 1, 2026 (e)
10.02 M USD
-14.01 M USD
-9.00 M USD
Jan 1, 2027 (e)
63.73 M USD
26.94 M USD
32.36 M USD
Jan 1, 2028 (e)
130.55 M USD
91.38 M USD
69.29 M USD
Jan 1, 2029 (e)
176.53 M USD
153.45 M USD
54.72 M USD
Jan 1, 2030 (e)
241.77 M USD
218.32 M USD
75.02 M USD
Jan 1, 2031 (e)
284.78 M USD
0.00 USD
82.97 M USD

VolitionRX Margins

VolitionRX stock margins

The VolitionRX margin analysis displays the gross margin, EBIT margin, as well as the profit margin of VolitionRX. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for VolitionRX.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2024
0.00 %
-2,190.92 %
-2,186.28 %
Jan 1, 2025 (e)
0.00 %
-1,110.48 %
-893.25 %
Jan 1, 2026 (e)
0.00 %
-139.85 %
-89.87 %
Jan 1, 2027 (e)
0.00 %
42.28 %
50.78 %
Jan 1, 2028 (e)
0.00 %
70.00 %
53.07 %
Jan 1, 2029 (e)
0.00 %
86.93 %
31.00 %
Jan 1, 2030 (e)
0.00 %
90.30 %
31.03 %
Jan 1, 2031 (e)
0.00 %
0.00 %
29.13 %

VolitionRX Stock analysis

What does VolitionRX do? VolitionRX Ltd was founded in 2010 with headquarters in Austin, Texas. It is a multinational life science company specializing in the discovery of cancer and other disease markers. The company's mission is to improve the quality of life for millions of people worldwide through the development of pain diagnostic systems. History VolitionRX began as a collaboration between scientists Professor Avraham Rasooly from the University of California and Professor David Kroll from North Carolina State University. The two professors were searching for a more effective diagnostic method for cancer and eventually co-founded VolitionRX in 2010. Initially, the company focused on developing diagnostic tests for stomach and colorectal cancer. Business model VolitionRX is a research-based company that specializes in the development of diagnostic and testing systems for cancer. The company works closely with leading cancer experts and scientific institutions to achieve groundbreaking research results. The goal is to develop innovative diagnostic methods that enable doctors to detect cancer faster and more effectively. Divisions VolitionRX is divided into three main areas: diagnostic tests, research and development, and partner and customer relations. Diagnostic tests VolitionRX offers a variety of diagnostic tests for cancer and other diseases. The tests are based on nucleosomics technology, which allows for analysis of cellular DNA. VolitionRX has developed various tests for colorectal cancer, lung cancer, pancreatic cancer, and other types of cancer, and is working on new tests for other conditions. Research and development VolitionRX continuously invests in research and development of new diagnostic methods for cancer and other diseases. The company collaborates closely with leading scientific institutions and cancer experts to develop innovative solutions for cancer diagnostics. Partner and customer relations VolitionRX works with a range of partners to distribute its diagnostic tests worldwide. The company has partnerships with various diagnostic laboratories and medical institutions to make its tests available to a wider target audience. Products VolitionRX offers a variety of products for the diagnosis of cancer and other diseases. These include: 1. NuQ blood tests for the diagnosis of colorectal cancer and other types of cancer. 2. Nucleosomics technology for analysis of cellular DNA for early cancer detection. 3. Software for data analysis from medical tests. Future prospects VolitionRX aims to further improve its technology for cancer diagnosis in order to save lives and improve the quality of life for people worldwide. The company's future prospects are promising as the demand for fast and effective cancer diagnostic methods continues to increase due to the rising number of cancer cases worldwide. VolitionRX is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing VolitionRX's EBIT

VolitionRX's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of VolitionRX's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

VolitionRX's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in VolitionRX’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about VolitionRX stock

EBIT of VolitionRX is -27.03 M USD in 2026.

EBIT of VolitionRX changed from -35.99 M USD to -27.03 M USD, representing a -24.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT VolitionRX since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's VolitionRX historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — VolitionRX

All Key Metrics — VolitionRX